Answers are grounded in this paper and cite their sources.
Experimental model indicates altered protein profiles in cerebrospinal fluid and hippocampus, suggesting implications for Alzheimer's pathogenesis.
Alzheimer’s disease (AD), one of the most common forms of dementia, where loss of memory is the first and most characteristic symptom, is emerging as one of the biggest public health burdens in the aging Western society. Although the diagnosis is frequently made with cognitive tests and imaging, the use of biochemical markers in clinical practice is emerging for early diagnosis and prevention. This research aimed to study the effects of the experimental model of AD on the protein profile of the hippocampus and cerebrospinal fluid (CSF). We used an experimental model of sporadic AD induced by intracerebroventricular (ICV) injection of streptozotocin (STZ) in adult male Wistar rats. We performed SDS-PAGE and compared the results to known alterations in the protein profiles of AD patients. This model of AD caused the occurrence of impaired spatial memory and some unexpected protein changes demonstrated by unusual spikes in the densitogram, suggesting posttranslational changes of albumin and other transporter proteins in the hippocampus and CSF. These data suggest that such posttranslational changes may partly contribute to the pathogenesis of AD and can serve as a starting point for further evaluation of the STZ model’s strengths and limitations in studying this disorder.
No takes yet. Share an insight, caveat, or question.
Bakalov et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: